Phase II double-blind, randomised, placebo-controlled study the safety and immunogenicity of H1/IC31 (trademarked), in HIV-infected adults without TB

Authors
Category Primary study
Registry of TrialsPan African Clinical Trials Registry
Year 2011
This article has no abstract
Epistemonikos ID: 62e8a55241a9b25c87f22cc8f882ca4973128b7e
First added on: Apr 16, 2025